BRIDGEBIO PHARMA INC's ticker is and the CUSIP is 10806XAB8. A total of 45 filers reported holding BRIDGEBIO PHARMA INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,400,000 | -44.6% | 2,500,000 | -54.5% | 0.01% | -47.6% |
| Q2 2023 | $4,332,448 | +6.3% | 5,500,000 | 0.0% | 0.02% | 0.0% |
| Q1 2023 | $4,075,500 | +6.5% | 5,500,000 | -35.3% | 0.02% | -25.0% |
| Q4 2022 | $3,825,000 | -24.9% | 8,500,000 | 0.0% | 0.03% | -9.7% |
| Q3 2022 | $5,090,000 | -12.5% | 8,500,000 | -19.0% | 0.03% | +10.7% |
| Q2 2022 | $5,815,000 | -13.4% | 10,500,000 | -8.7% | 0.03% | +55.6% |
| Q1 2022 | $6,716,000 | -32.5% | 11,500,000 | -14.8% | 0.02% | +5.9% |
| Q4 2021 | $9,952,000 | -28.0% | 13,500,000 | +35.0% | 0.02% | -37.0% |
| Q3 2021 | $13,822,000 | -24.0% | 10,000,000 | -9.1% | 0.03% | -50.0% |
| Q1 2021 | $18,198,000 | – | 11,000,000 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BRAIDWELL LP | 114,338,000 | $138,406,149 | 5.08% |
| Affinity Asset Advisors, LLC | 17,000,000 | $20,578,500 | 3.76% |
| Graham Capital Management, L.P. | 73,241,000 | $88,469,027 | 1.96% |
| 683 Capital Management, LLC | 14,750,000 | $17,820,655 | 1.46% |
| ARISTEIA CAPITAL, L.L.C. | 53,423,000 | $64,668,542 | 1.14% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 24,929,000 | $30,176,555 | 0.69% |
| LINDEN ADVISORS LP | 47,125,000 | $56,947,457 | 0.54% |
| MACKAY SHIELDS LLC | 14,449,000 | $17,490,515 | 0.51% |
| SSI INVESTMENT MANAGEMENT LLC | 4,751,000 | $5,727,331 | 0.43% |
| Weiss Asset Management LP | 7,000,000 | $8,461,051 | 0.40% |